Strategy for in vitro cell age validation for a CHO cell line producing a therapeutic monoclonal antibody.

被引：0
作者：
Moore, AW [1 ]
Trala, R [1 ]
Pennetti, D [1 ]
deVries, RL [1 ]
机构：
[1] GlaxoSmithKline, Biopharmaceut Dev, King Of Prussia, PA 19406 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2002年 / 224卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
211-BIOT
引用
收藏
页码：U233 / U233
页数：1
相关论文
共 50 条
  • [31] The long term clinical outcome of B cell lymphoma patients treated with anti-idiotype monoclonal antibody correlated with the isotype of the therapeutic antibody.
    Weng, Wen-Kai
    Czerwinski, Debbie
    Levy, Ronald
    BLOOD, 2006, 108 (11) : 208A - 208A
  • [32] Single use bioreactors for the clinical production of monoclonal antibodies – a study to analyze the performance of a CHO cell line and the quality of the produced monoclonal antibody
    Sonja Diekmann
    Constanze Dürr
    Alexander Herrmann
    Ingo Lindner
    Daniela Jozic
    BMC Proceedings, 5 (Suppl 8)
  • [33] Generation of monoclonal antibody-producing mammalian cell lines
    Ho, Steven C. L.
    Tong, Yen Wah
    Yang, Yuansheng
    PHARMACEUTICAL BIOPROCESSING, 2013, 1 (01) : 71 - 87
  • [34] Cell Line Profiling to Improve Monoclonal Antibody Production
    Kang, Sohye
    Ren, Da
    Xiao, Gang
    Daris, Kristi
    Buck, Lynette
    Enyenihi, Atim A.
    Zubarev, Roman
    Bondarenko, Pavel V.
    Deshpande, Rohini
    BIOTECHNOLOGY AND BIOENGINEERING, 2014, 111 (04) : 748 - 760
  • [35] Role of oxidative stress in modulating CHO cell culture performance: Impact on titer and quality attributes of a monoclonal antibody therapeutic
    Kaur, Rajinder
    Rathore, Anurag S.
    JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, 2023, 98 (03) : 651 - 660
  • [36] Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell
    Chin, J
    Sohn, Y
    Lee, SH
    Park, YI
    Choi, MJ
    BIOLOGICALS, 2003, 31 (01) : 45 - 53
  • [37] Impact of aeration strategy on CHO cell performance during antibody production
    Velez-Suberbie, M. Lourdes
    Tarrant, Richard D. R.
    Tait, Andrew S.
    Spencer, Daniel I. R.
    Bracewell, Daniel G.
    BIOTECHNOLOGY PROGRESS, 2013, 29 (01) : 116 - 126
  • [38] Novel cell line development strategy for monoclonal antibody manufacturing using translational enhancing technology
    Masuda, Kenji
    Watanabe, Kazuhiko
    Ueno, Tomonori
    Nakazawa, Yuto
    Tanabe, Yumiko
    Ushiki-Kaku, Yuko
    Ogawa-Goto, Kiyoko
    Ehara, Yukikazu
    Saeki, Hisashi
    Okumura, Takeshi
    Nonaka, Koichi
    Kamihira, Masamichi
    JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 2022, 133 (03) : 273 - 280
  • [39] Identification and characterization of CHO host-cell proteins in monoclonal antibody bioprocessing
    Oh, Young Hoon
    Mendola, Kerri M.
    Choe, Leila H.
    Min, Lie
    Lavoie, Ashton R.
    Sripada, Sobhana A.
    Williams, Taufika Islam
    Lee, Kelvin H.
    Yigzaw, Yinges
    Seay, Alexander
    Bill, Jerome
    Li, Xuanwen
    Roush, David J.
    Cramer, Steven M.
    Menegatti, Stefano
    Lenhoff, Abraham M.
    BIOTECHNOLOGY AND BIOENGINEERING, 2024, 121 (01) : 291 - 305
  • [40] Eliminating tyrosine sequence variants in CHO cell lines producing recombinant monoclonal antibodies
    Feeney, Lauren
    Carvalhal, Veronica
    Yu, X. Christopher
    Chan, Betty
    Michels, David A.
    Wang, Yajun Jennifer
    Shen, Amy
    Ressl, Jan
    Dusel, Brendon
    Laird, Michael W.
    BIOTECHNOLOGY AND BIOENGINEERING, 2013, 110 (04) : 1087 - 1097
12345